WEAK BUY
Looks very cheap. It has had troubles because of the US$ differential. Very well managed. One of the few companies in this sector still making money. The street still has $11/ targets on it. They need a much weaker Cdn$ to do well.
TRADE
The manufacturing can side of aluminum. A spin off from Alcan (AL-T). Less cyclical so would prefer this one at today's prices. However, Alcan has some recovery coming, so would prefer it now.
DON'T BUY
Steel prices have rolled over in the last while. Probably a bit of a bounce coming, so there could be one more positive trade in this stock. Fairly risky.
BUY
Have done really well in broadening out. Showing some growth. Has a decent dividend.
TOP PICK
80% gas. Probably one of the few intermediate to senior companies that he is comfortable buying right now. Only at 4.5 X cash flow. A lot of upside from oil sands type projects. A lot of land positions so they have 5, 6, 7 years of drilling available. Can see years of growth.
TOP PICK
Had a good run but has gone sideways for 4/5 months. Classic growth stock. Reports on Tuesday and is expecting $0.37/0.38 versus $0.32 a year ago. Not cheap. Has a growth multiple. Looking for $1.60 this year and $2 next year.
TOP PICK
A safer way to get some cyclical growth. A little more cyclical than Canadian National (CNR-T) so if you are playing it at this time in the cycle, you want the little more cyclical that CP offers. A little more resource and grain oriented. Cheap multiple.
DON'T BUY
A risky situation based on the strong Cdn$ and duties on lumber.
DON'T BUY
A great Canadian company with a world wide presence. Stock is not doing very well because it is always expensive. Trading at 20 X earnings. Good dividend yield at over 2%.
TOP PICK
Exclude any valuation on the C series project. Likes because there is an improvement in the margins of the main transportation business. Has cash flow. Financial problems are behind them.
BUY
A good holding for those that don't like risks. Good dividend. Great brand name. Too neglected by the market.
BUY
This is a good entry point. Be prepared to see another minus 10/15%. The potential is a $5 increase.
TOP PICK
The easiest way to play the age demographics. Instead of buying biotechs and pharma stocks, a drug store is a better choice. The buying of Ekards in the US was a real coup. Patience will pay. A good investment.
BUY
A great buy. If you are a short term investor who likes to trade, the price is pretty attractive. For a long term investor, it's a good one to have in the portfolio.
BUY
There's so much potential in the flat panel business, but a lot of competition also. Now that it's gone through $4, it's a Buy, but there is a risk attached to it.